[{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","commit":"3b662d41c0","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for the last approved products without one","file":"src/data/spikes/nsclc.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Tremelimumab\" }]"}]},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/nsclc.ts","type":"changed","fields":[{"field":"tldr","before":"\"AstraZeneca's CTLA-4 antibody, given as a single priming dose with durvalumab and chemotherapy in lung and liver cancer.\"","after":"\"Tremelimumab is AstraZeneca's CTLA-4 antibody, given as a single priming dose with durvalumab and chemotherapy in lung and liver cancer.\""}]}]